BioAtla (NASDAQ:BCAB) Coverage Initiated by Analysts at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of BioAtla (NASDAQ:BCAB) in a research note issued to investors on Tuesday morning, Marketbeat reports. The firm issued a buy rating and a $4.00 target price on the stock.

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioAtla in a research note on Friday. One equities research analyst has rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $4.00.

BioAtla Trading Down 2.1%

Shares of BCAB stock opened at $0.31 on Tuesday. The firm’s 50 day moving average is $0.73 and its 200 day moving average is $0.61. The stock has a market capitalization of $18.12 million, a P/E ratio of -0.27 and a beta of 1.04. BioAtla has a 12 month low of $0.24 and a 12 month high of $1.43.

BioAtla (NASDAQ:BCAB) last issued its earnings results on Thursday, November 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.04. On average, equities analysts predict that BioAtla will post -1.46 EPS for the current year.

Institutional Investors Weigh In On BioAtla

A number of institutional investors and hedge funds have recently made changes to their positions in BCAB. Woodline Partners LP bought a new stake in BioAtla during the first quarter valued at $26,000. Sheets Smith Investment Management bought a new stake in shares of BioAtla during the 3rd quarter valued at about $46,000. Susquehanna International Group LLP grew its holdings in shares of BioAtla by 237.6% during the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock worth $174,000 after purchasing an additional 177,760 shares in the last quarter. Millennium Management LLC bought a new position in shares of BioAtla in the third quarter worth approximately $235,000. Finally, Acadian Asset Management LLC raised its stake in BioAtla by 968.9% in the first quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock valued at $585,000 after purchasing an additional 1,531,994 shares in the last quarter. Hedge funds and other institutional investors own 77.23% of the company’s stock.

About BioAtla

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.